RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I

Cancer Research

Volumn 56, Issue 7, 1996, Pages 1674-1681

  Buckwalter, Christopher A ^a   Lin, Amy H ^b   Tanizawa, Akihiko ^c   Pommier, Yves G ^c   Cheng, Yung Chi ^d   Kaufmann, Scott H ^a,e  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DICHLOROBENZIMIDAZOLE RIBOSIDE; APHIDICOLIN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CYCLOHEXIMIDE; DNA TOPOISOMERASE; RNA SYNTHESIS INHIBITOR; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME LOCALIZATION; HAMSTER; HUMAN; HUMAN CELL; LEUKEMIA CELL; LUNG NON SMALL CELL CANCER; NONHUMAN; NUCLEOLUS; PRIORITY JOURNAL; RNA SYNTHESIS;

ANIMALS; CAMPTOTHECIN; CELL NUCLEUS; CRICETINAE; DICHLORORIBOFURANOSYLBENZIMIDAZOLE; DNA TOPOISOMERASES, TYPE I; HUMANS; MICE; RNA; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 0029883835     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Slichenmyer, W J , Rowinsky, E. K., Donehower, R. C., and Kaufmann, S. H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst., 85: 271-291, 1993.
2. Chen, A. Y., and Liu, L. F DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol , 34: 191-218, 1994.
3. Potmesil, M. Camptothecins: from bench research to hospital wards. Cancer Res., 54: 1431-1439, 1994
4. Gupta, M., Fujimon, A., and Pommier, Y. Eukaryotic DNA topoisomerase-I Biochim. Biophys. Acta, 1262: 1-14, 1995.
5. Burris, H. A., Rothenberg, M. L., Kuhn, J. G., and Von Hoff, D. D Clinical trials with the topoisomerase I inhibitors. Semin. Oncol., 19: 663-669, 1992.
6. Fleischmann, G., Pflugfelder, G., Steiner, E. K., Javaherian, K., Howard, G. C., Wang, J. C., and Elgin, S. C. Drosophila DNA topoisomerase I is associated with transcriptionally active regions of the genome. Proc. Natl. Acad. Sci. USA, 81: 6958-6962, 1984.
7. Muller, M. T., Pfund, W. P., Mehta, V. B., and Trask, D. K. Eukaryotic type I: topoisomerase is enriched in the nucleolus and catalytically active on ribosomal DNA EMBO J., 4: 1237-1243, 1985.
8. Negri, C., Chiesa, R , Cerino, A., Bestagno, M., Sala, C., Zini, N., Maraldi, N. M., and Astaldi Ricotti, G C. Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II, 170- and 180-kDa isozymes. Exp. Cell Res., 200: 452-459, 1992.
9. Weisenberger, D., Scheer, U., and Benavente, R. The DNA topoisomerase I inhibitor camptothecin blocks postmitotic reformation of nucleoli in mammalian cells. Eur. J. Cell Biol., 61: 189-192, 1993.
10. Rowinsky, E. K., Adjei, A., Donehower, R. C., Gore, S. D., Jones, R. J., Burke, P. J., Cheng, Y-C., Grochow, L. B , and Kaufmann, S. H. Phase I and pharmacodynamic study of the topoisomerase I inhibitor topotecan in patients with refractory acute leukemia. J. Clin. Oncol., 12: 2193-2203, 1994.
11. Zini, N , Santi, S , Ognibene, A., Bavelloni, A., Neri, L. M., Valmori, A., Mariani, E., Negri, C., Astaldi-Ricotti, G. C. B., and Maraldi, N. M. Discrete localization of different DNA: topoisomerases in HeLa and K562 cell nuclei and subnuclear fractions. Exp. Cell Res., 210: 336-348, 1994
12. Culotta, V., and Sollner-Webb, B. Sites of topoisomerase I action on X. laevis ribosomal chromatin: transcriptionally active rDNA has an approximately 200 bp repeating structure. Cell, 52: 585-597, 1988.
13. Zhang, H., Wang, J. C., and Liu, L. F. Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes. Proc. Natl. Acad. Sci. USA, 85: 1060-1064, 1988
14. Rose, K. M., Szopa, J., Han, F. S., Cheng, Y. C., Richter, A., and Scheer, U. Association of DNA topoisomerase I and RNA polymerase I: a possible role for topoisomerase I in ribosomal gene transcription. Chromosoma, 96: 411-416, 1988.
15. Thiry, M., Scheer, U., and Goessens, G. Localization of nucleolar chromatin by immunocytochemistry and in situ hybridization at the electron microscopic level. Electron Microsc Rev., 4: 85-110, 1991.
16. Baker, S. D., Wadkins, R. M , Stewart, C. F , Beck, W. T., and Danks, M. K. Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy. Cytometry, 19: 134-145, 1995.
17. Kaufmann, S. H., Charron, M., Burke, P. J., and Karp, J. E. Changes in topoisomerase I levels and localization during myeloid maturation in vitro and in vivo. Cancer Res., 55. 1255-1260, 1995.
18. Chan, P. K., Aldrich, M., and Busch, H. Alterations in immunolocalization of the phosphoprotein B23 in HeLa cells during serum starvation. Exp. Cell Res , 161. 101-110, 1985.
19. Feuerstein, N., Spiegel, S. and Mond, J. J. The nuclear matrix protein, numatrin (B23), is associated with growth factor-induced mitogenesis in Swiss 3T3 fibroblasts and with T lymphocyte proliferation stimulated by lectins and anti-T cell antigen receptor antibody. J. Cell Biol., 107: 1629-1642, 1988.
20. Biggiogera, M , Fakan, S , Kaufmann, S H , Black, A , Shaper, J. H., and Busch, H Simultaneous immunoelectron microscopic visualization of protein B23 and C23 distribution in the HeLa cell nucleolus. J. Histochem. Cytochem., 37: 1371-1374, 1989.
21. Yung, B Y-M., Busch, H , and Chan, P-K. Effects of luzopeptins on protein B23 translocation and ribosomal RNA synthesis in HeLa cells. Cancer Res., 46: 922-925, 1986.
22. Sweet, P , Chan, P. K , and Slater, L. M. Cyclosporin A and verapamil enhancement of daunorubicin-produced nucleolar protein B23 translocation in daunorubicin-resistant and -sensitive human and murine tumor cells. Cancer Res., 49: 677-680, 1989.
23. Yung, B Y-M., Bor, A M-S., and Chan, P-K Short exposure to actinomycin D induced "reversible" translocation of protein B23 as well as "reversible" inhibition of cell growth and RNA synthesis in HeLa cells. Cancer Res., 50 5987-5991, 1990.
24. Chan, P. K. Characterization and cellular localization of nucleophosmin/B23 in HeLa cells treated with selected cytotoxic agents: studies of B23-translocation mechanism. Exp. Cell Res., 203: 174-181, 1992.
25. Finch, R. A., Revankar, G. R., and Chan, P. K. Nucleolar localization of nucleophosmin/B23 requires GTP. J. Biol. Chem., 268: 5823-5827, 1993.
26. Hendricks, C. B., Rowinsky, E. K., Grochow, L B., Donehower, R. C., and Kaufmann, S. H. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res , 52: 2268-2278, 1992.
27. Tanizawa, A., Beitrand, R., Kohlhagen, G., Tabuchi, A., Jenkins, J., and Pommier, Y. Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. J. Biol. Chem., 268: 25463-25468, 1993.
28. Chang, J-Y., Dethlefsen, L. A., Barley, L. R., Zhou, B. S., and Cheng, Y-C. Characterization of camptothecin-resistant Chinese hamster lung cells. Biochem. Pharmacol., 43: 2443-2452, 1992.
29. Fields, A. P , Kaufmann, S. H., and Shaper, J. H. Analysis of the internal nuclear matrix. oligomers of a 38 kD nucleolar polypeptide stabilized by disulfide bonds. Exp. Cell Res., 164: 139-153, 1986.
30. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
31. Kaufmann, S H., McLaughlin, S J., Kastan, M., Liu, L. F., Karp, J. E , and Burke, P. J. Topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Res , 51: 3534-3543, 1991.
32. Kaufmann, S. H., and Shaper, J. H. Erasure of Western blots after autoradiography or chemiluminescent detection. Appl. Biochem. Biotechnol., 38: 243-255, 1993.
33. Tamm, I., Hand, R., and Caliguiri, L. A. Action of dichlorobenzimidazole riboside on RNA synthesis in L-929 and HeLa cells. J. Cell Biol., 69: 229-240, 1976.
34. Zandomeni, R., Bunick, D., Ackerman, S., Mittleman, B., and Weinmann, R. Mechanism of action of DRB III. effect on specific in vitro initiation of transcription J. Mol. Biol., 167 561-574, 1983.
35. Spadari, S., Sala, F., and Pedrali-Noy, G. Aphidicolin: a specific inhibitor of nuclear DNA replication in eukaryotes. Trends Biochem. Sci., 29-32: 1982.
36. Holm, C., Covey, J. M., Kerrigan, D., and Pommier, Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells Cancer Res., 49: 6365-6368, 1989.
37. Schneider, E., Hsiang, Y. H , and Liu, L. DNA topoisomerases as anticancer drug targets. Adv Pharmacol., 21: 149-183, 1990.
38. Kaufmann, S. H. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res., 51: 1129-1136, 1991.
39. Pommier, Y., Jaxel, C , Heise, C. R., Kerrigan, D., and Kohn, K W. Structure-activity relationship of topoisomerase I. Inhibition by camptothecin derivatives: evidence for the existence of a ternary complex. In: M. Potmesil and K. W. Kohn (eds ), DNA Topoisomerases in Cancer, pp 121-132. New York: Oxford University Press, 1991.
40. Wall, M. E., Wani, M. C., Nicholas, A W , Manikumar, G., Tele, C., Moore, L., Truesdale, A., Leitner, P , and Besterman, J. M. Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs. J. Med. Chem., 36: 2689-2700, 1993.
41. Danks, M. K., Garrett, K. E., Marion, R. C., and Whipple, D. O. Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. Cancer Res., 56: 1664-1673, 1996.
42. Davis, L., Cadrin, M., Brown, D. L., and Chaly, N. Reversible disassembly of transcription domains in lymphocyte nuclei during inhibition of RNA synthesis by DRB. Biol. Cell, 78: 163-180, 1993.
43. Recher, L., Chan, H., Briggs, L., and Parry, N Ultrastructural changes inducible with the plant alkaloid camptothecin. Cancer Res , 32 2495-2501, 1972.
44. Shaw, P. J., and Jordan, E G. The Nucleolus. Annu. Rev. Cell Dev. Biol., 11: 93-121, 1995.
45. Dingwall, C , and Laskey, R. A. Nuclear targeting sequences-a consensus? Trends Biochem. Sci., 16: 478-484, 1991.
46. Creancier, L , Prats, H , Zanibellato, C , Amalric, F., and Bugler, B. Determination of the functional domains involved in nucleolar targeting of nucleolin. Mol. Biol. Cell, 4: 1239-1250, 1993.
47. Schmidt-Zachmann, M. S., and Nigg, E. A Protein localization to the nucleolus. a search for targeting domains in nucleolin. J. Cell Sci., 105. 799-806, 1993.
48. Adachi, Y , Copeland, T. D., Hatanaka, M., and Oroszlan, S. Nucleolar targeting signal of Rex protein of human T-cell leukemia virus type I specifically binds to nucleolar shuttle protein B23. J Biol. Chem., 268: 13930-13934, 1993.
49. Valdez, B. C., Perlaky, L., Henning, D., Saijo, Y., Chan, P-K., and Busch, H. Identification of the nuclear and nucleolar localization signals of the protein p120. J. Biol Chem , 269: 23776-23783, 1994
50. Alsner, J., Svejstrup, J Q., Kjeldsen, E., Sorensen, B S , and Westergaard, O. Identification of an N-terminal domain of eukaryotic DNA topoisomerase I dispensable for catalytic activity but essential for in vivo function. J. Biol. Chem., 267: 12408-12411, 1992.
51. D'Arpa, P , Machlin, P. S , Ratrie, H., Rothfield, N F , Cleveland, D W., and Earnshaw, W. C. cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67 7-kDa carboxyl-terminal fragment. Proc. Natl Acad. Sci USA, 85: 2543-2547, 1988
52. Muller, M T. Quantitation of eukaryotic topoisomerase I reactivity with DNA: preferential cleavage of supercoiled DNA. Biochim. Biophys. Acta, 824: 263-267, 1985.
53. Liu, L F., and Wang, J C Supercoiling of the DNA template during transcription Proc. Natl. Acad Sci USA, 84: 7024-7027, 1987.
54. Brill, S. J., and Sternglanz, R. Transcription-dependent DNA: supercoiling in yeast DNA topoisomerase mutants. Cell, 54: 403-411, 1988.
55. Beidler, D R., and Cheng, Y-C. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol. Pharmacol., 47: 907-914, 1995.
56. Yang, C-H. J., Horton, J. K., Cowan, K. H., and Schneider, E. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res , 55: 4004-4009, 1995.
57. Madden, K. R., Stewart, L , and Champoux, J. J. Preferential binding of human topoisomerase I to superhelical DNA. EMBO J., 14: 5399-5409, 1995.